Navigation Links
Dendreon Reports Third Quarter 2007 Financial Results
Date:11/15/2007

- Management Will Host Conference Call at 1:30 PM ET -

SEATTLE, Nov. 15 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended September 30, 2007. Revenue for the third quarter of 2007 was $112,000 compared to $84,000 for the quarter ended September 30, 2006. Revenue for the nine months ended September 30, 2007 was $715,000 compared to $187,000 for the nine months ended September 30, 2006.

Dendreon's total operating expenses for the third quarter of 2007 were $19.8 million compared to $21.7 million in 2006. Dendreon's total operating expenses for the nine months ended September 30, 2007 were $75.2 million compared to $73.6 million for the same period in 2006.

The net loss for the quarter ended September 30, 2007 was $19.2 million, or $0.23 per share, compared to a net loss of $20.7 million, or $0.29 per share, for the quarter ended September 30, 2006. The net loss for the nine months ended September 30, 2007 was $72.3 million, or $0.88 per share, compared to $70.2 million, or $0.98 per share for the nine months ended September 30, 2006.

Cash, cash equivalents and short-term and long-term investments at September 30, 2007 totaled $138.8 million compared to $121.3 million at December 31, 2006.

Recent Highlights:

-- Completed enrollment of over 500 patients in the Phase 3 IMPACT

(IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as

D9902B) clinical trial of PROVENGE(R) (sipuleucel-T). Dendreon

received confirmation that the FDA will accept either a positive

interim or positive final analysis of overall survival from the IMPACT

study to amend the Biologics License App
'/>"/>

SOURCE Dendreon Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. QMed, Inc. Reports July Medicare SNP Enrollments
7. Phlo Affiliate Reports Expanded Coverage to Oregon Border
8. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Carrington Reports Second Quarter 2007 Results
11. Avitar Reports Third Quarter Financial Results for Fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Calif., July 10, 2014   Ceres, Inc . ... seed company, announced today financial results for the three ... on its business. Ceres reported that the ... product performance this growing season in Brazil, which concluded ... the company,s sorghum evaluation areas for part of the ...
(Date:7/10/2014)... new study published today in the journal PNAS ... found that time of day and sleep deprivation have ... be crucial when looking at the best time of ... heart disease, and for administering medicines effectively. , Researchers ... Cancer Research, London, investigated the links between sleep deprivation, ...
(Date:7/10/2014)... and spiders can sit upside down forever. Nanophysics makes sure ... in an article just published in Physical Review E ... Geckos and spiders that seem to be able to sit ... worldwide for many years. We will soon be able to ... the gecko,s foot. But the fact is, sooner or later ...
(Date:1/15/2014)... , Using an approach akin to assembling a ... Standards and Technology (NIST) researchers have succeeded in ... reduces the flammability of foam commonly used in ... flammability of the nanotube-coated polyurethane foam was reduced ...
Breaking Biology Technology:Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Time of day crucial to accurately test for diseases, new research finds 2Even geckos can lose their grip 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2
... OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today ... BIO Investor Forum on Wednesday, October 6 at 10:30 a.m. ... Live webcasts from this conference will be available through ... http://ir.oncogenex.com . Webcast replays will be available approximately two ...
... Inc. (PDL) (Nasdaq: PDLI ) today announced that ... of $0.50 per share to all stockholders owning shares of ... As previously announced, the conversion rate for the ... adjusted to 140.571 shares of common stock per $1,000 principal ...
... the United States became infected with West Nile virus, a potentially ... the Culex mosquito that has first fed ... in their salivary glands and transmit the disease to humans and ... the genetic makeup of the Culex mosquito, and how ...
Cached Biology Technology:OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum 2Researchers sequence genome of mosquito that spreads West Nile virus 2Researchers sequence genome of mosquito that spreads West Nile virus 3
(Date:7/11/2014)... 11, 2014 The increased risk of kidney injury ... resuscitation fluids reflects the mass of HES molecules, according ... official journal of the International Anesthesia Research Society (IARS). ... harmful effect of HES on cultured human renal proximal ... Christian Wunder and colleagues of University Hospital Wrzburg, Austria. ...
(Date:7/11/2014)... Research and Markets has announced ... - Industry Analysis Size Share Growth Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 The rising ... need for high level security in both private and ... as username and passwords, tokens etc. are vulnerable to ...
(Date:7/10/2014)... , June 27, 2014  Pomerantz LLP has ... Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) and certain ... United States District Court, Middle District of ... behalf of a class consisting of all persons ... securities between December 17, 2013 and May 22, ...
Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... -- In the middle of the South Pacific, about ... that soon will emerge as a model ecosystem, thanks ... by University of California, Berkeley, biologists. Moorea, home ... Research Station and France,s Centre de Recherches Insulaires et ...
... NEW YORK (Dec. 7, 2007) -- Alcohol triggers the ... the health and activity of brain cells, and new ... City sheds light on how that process occurs. ... The Journal of Neuroscience, may also edge scientists closer ...
... researchers at The University of Nottingham are teaming up ... region, to work on pioneering Sport PhD courses. ... the use of illegal performance-enhancing drugs in sports, and ... affordable. Theyre just two of seven collaborative ...
Cached Biology News:US-French research team to barcode an entire ecosystem 2US-French research team to barcode an entire ecosystem 3US-French research team to barcode an entire ecosystem 4Research reveals secrets of alcohol's effect on brain cells 2Research reveals secrets of alcohol's effect on brain cells 3
Human Xg Affinity Purified Polyclonal Ab Keywords: Xg glycoprotein, hereditary hemorrhagic telangiectasia Protein Family: ...
in vitro Translation, Accessory Products...
...
Mouse Collagen IV...
Biology Products: